bims-ovdlit Biomed News
on Ovarian cancer: early diagnosis, liquid biopsy and therapy
Issue of 2026–11–01
eight papers selected by
Lara Paracchini, Humanitas Research



  1. Lancet Oncol. 2026 10 29. pii: S1470-2045(26)00593-0. [Epub ahead of print]
      
    DOI:  https://doi.org/10.1016/S1470-2045(26)00593-0
  2. Curr Opin Obstet Gynecol. 2026 Oct 27.
       PURPOSE OF REVIEW: Circulating tumor DNA (ctDNA) is increasingly used for molecular profiling in breast cancer, and its role as a longitudinal biomarker is expanding. This review examines recent evidence on serial ctDNA assessment, focusing on minimal residual disease (MRD) and molecular relapse in early breast cancer (EBC) and on molecular response and emerging resistance in metastatic breast cancer (MBC).
    RECENT FINDINGS: In EBC, ctDNA dynamics and MRD detection carry prognostic value, and serial surveillance can identify molecular relapse before overt recurrence. However, molecular lead time is not necessarily a therapeutic interception window, and the benefit of treating molecular relapse remains unproven. In MBC, serial ctDNA analysis can capture tumor dynamics, clonal evolution, and emerging resistance. Emerging cell-free DNA methylation-based approaches may enable molecular breast cancer subtyping, complementing genomic profiling. Definitions of molecular response and progression lack standardization across assays, metrics, thresholds, and sampling schedules. Nevertheless, randomized evidence shows that adapting treatment to selected actionable resistance alterations detected before radiological progression can improve clinical outcomes.
    SUMMARY: ctDNA monitoring is shifting liquid biopsy from a static molecular characterization toward the longitudinal assessment of disease evolution. Its future clinical value will depend on identifying molecular changes reliable and actionable enough to translate earlier detection into patient benefit.
    Keywords:  breast cancer; circulating tumor DNA; liquid biopsy; minimal residual disease; molecular monitoring
    DOI:  https://doi.org/10.1097/GCO.0000000000001160
  3. Nat Rev Cancer. 2026 Oct 26.
      Single-cell genomics has entered the field of cancer research and clinical oncology, enhancing our understanding of the somatic evolution of cancer and intra-tumour genomic heterogeneity. The evolutionary history of a tumour can be represented as a phylogenetic tree, and in recent years, multiple statistical and computational methods have been proposed to reconstruct tumour phylogenies from single-cell sequencing data. The nature of tumour evolution and of single-cell sequencing, however, raises new challenges in modelling the data and the underlying evolutionary processes that are not addressed by classical phylogenetic and phylodynamic approaches. Here, we review the models and assumptions behind bespoke single-cell tumour phylogeny methods, along with recent computational and algorithmic advances in phylogenetic inference. We discuss the role these advances have in basic and clinical oncology research, and how they provide new insights into individual cancers and cohorts of patient samples. We conclude with an outlook of current challenges for single-cell phylogenetics and potential future applications.
    DOI:  https://doi.org/10.1038/s41568-026-00992-2
  4. Gastroenterol Clin North Am. 2026 Dec;pii: S0889-8553(26)00063-4. [Epub ahead of print]55(4): 599-616
      Pancreatic cancer remains one of the deadliest malignancies, with most patients presenting at advanced stages and experiencing poor survival outcomes. Approximately 10% to 15% of cases are associated with inherited genetic susceptibility, highlighting the critical role of germline genetic testing and family history assessment. Multiple hereditary cancer syndromes, including those involving BRCA1, BRCA2, ATM, PALB2, CDKN2A, STK11, TP53, and select Lynch syndrome mismatch repair genes, confer increased risk of pancreatic cancer. Universal germline testing, cascade testing of at-risk relatives, and individualized risk assessment facilitate precision oncology and early detection. Screening for pancreatic cancer using select imaging modalities enables earlier-stage diagnosis and improves survival.
    Keywords:  Cascade testing; Early detection; Genetic susceptibility; Genetic testing; High-risk individuals; Pancreatic cancer; Risk-stratified screening
    DOI:  https://doi.org/10.1016/j.gtc.2026.07.002
  5. Ann Oncol. 2026 Oct 27. pii: S0923-7534(26)08644-8. [Epub ahead of print]
       BACKGROUND: CtDNA detection during adjuvant endocrine therapy (ET) strongly associates with recurrence in oestrogen receptor (ER) positive early breast cancer (EBC), with potential to direct switches in adjuvant treatment.
    PATIENTS AND METHODS: TRAK-ER is a multicentre study for patients with high-risk, ER-positive, HER2-negative EBC, who undergo 3 monthly ctDNA surveillance for up to 3 years during adjuvant ET. High-risk included ≥4 involved lymph nodes; tumour >5 cm; 1-3 involved lymph nodes with additional high-risk features. Upon ctDNA detection, patients have staging scans and in the absence of radiological recurrence, are randomised to receive palbociclib plus fulvestrant or standard ET. ctDNA analysis was performed using a tumour informed assay (Labcorp). We report a protocol-specified analysis of ctDNA detection during surveillance, and results of contemporaneous radiological recurrence.
    RESULTS: 1133 patients were registered by September 2025, 928 had panels designed (design failed in 16.1% (178/1106), and 912 started ctDNA surveillance including results from 5810 tests (median 7 per patient). ctDNA detection rate was 5.0% (45/897) in the first test, and 1.3% (66/4913) in subsequent tests (P<0.001). Patient level detection rate was 12.0% (109/912), with 1.1% (10/912) of patients having a clinical recurrence without prior ctDNA detection. Detection positively associated with nodal burden (P<0.001) and grade (P=0.04) and negatively associated with increasing time from surgery (P=0.01). Estimated cumulative ctDNA detection rate at 5 years post-surgery was 23.7% (95%CI 14.5-31.9%). In patients with ctDNA detected on the first test, 65.9% (29/44) had radiological recurrence compared to 26.6% (17/64) in patients first detected on subsequent tests (P<0.001).
    CONCLUSION: Results from TRAK-ER inform implementation of ctDNA surveillance in ER-positive EBC, including molecular relapse rates, factors associating with ctDNA detection and contemporaneous radiological recurrence. Ultrasensitive assays detecting ctDNA at low levels, are required to robustly identify patients prior to clinical recurrence. TRAK-ER is ongoing to assess the impact of treatment after molecular relapse detection.
    Keywords:  circulating tumour DNA; early breast cancer; liquid biopsy; minimal residual disease; molecular relapse
    DOI:  https://doi.org/10.1016/j.annonc.2026.10.1292
  6. Nat Methods. 2026 Oct 29.
      Analysis of cell-free DNA (cfDNA) methylation can enable noninvasive disease detection by leveraging tissue-specific epigenetic differences between malignant and nonmalignant cells. However, such analyses can be confounded by the repair of jagged DNA fragment ends during double-stranded sequencing library preparation, which introduces spurious methylation signals into cfDNA molecules. Here we present JEEPERS, a framework to detect and correct jagged-end-induced methylation errors while preserving duplex integrity and native methylation patterns. We showed high fidelity for measuring tumor burden and demonstrated allele-specific methylation differences at recurrent somatic mutations, revealing a link between adjacent CpG methylation and EGFR/TP53 driver and resistance mutations. We further demonstrated enhanced diagnostic performance across liquid biopsy applications, including tumor-type-specific methylation profiles, hemimethylation profiling, epigenetic-clock-based age estimation and cell type deconvolution. By faithfully correcting end-repair errors, JEEPERS provides a versatile framework for integrating mutations and methylation features in cfDNA at high resolution, enabling more precise molecular profiling and disease monitoring.
    DOI:  https://doi.org/10.1038/s41592-026-03278-5
  7. Am J Med Sci. 2026 Oct 27. pii: S0002-9629(26)00404-0. [Epub ahead of print]
      
    Keywords:  clinical care; genetics; hereditary cancer; quality; variant interpretation
    DOI:  https://doi.org/10.1016/j.amjms.2026.10.010